AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02033616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVOVA-1
Description: Comparison of a cancer treatment containing autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells vs. a cancer treatment containing autologous immune cells.
Study NCT02033616 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MC
Description: Comparison of a cancer treatment containing autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells vs. a cancer treatment containing autologous immune cells.
Study NCT02381470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefadroxil
Description: Cefadroxil 1g
Study NCT02381470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: Rifampicin 10mg/kg
Study NCT03239301 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation
Description: Conventional rehabilitation program consisted range of motion (ROM) exercises, balance and coordination training, progressive resistive exercises, posture training, gait training, and occupational therapy as much as the patients tolerated. Conventional rehabilitation was tailored to the patient considering his requires and expectancies.
Study NCT03239301 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic REhabilitation
Description: The Armeo Spring HocomAG Inc. (Volketswil, Switzerland) device was used in robot assisted upper limb rehabilitation program. Assistive component of the robotic arm was adjusted in accordance with motor level of each patient. Variety and difficulty of games were chosen according to the ability and functional status of the patients. Variety and difficulty level of the games were modified according to progress of patients by the same physiotherapist.
Study NCT00808405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acyclovir
Description: 400mg taken orally three times daily for 5 days
Study NCT00808405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: matching placebo taken orally three times daily for 5 days.
Study NCT02731846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg
Description: Dry white powder delivered via ELLIPTA inhaler(2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Umeclidinium 62.5 mcg and Vilanterol 25 mcg per blister), administered as one inhalation of FF/UMEC/VI (100/62.5/25 mcg) once-daily in the morning
Study NCT02514213 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P
Description: 8.5mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P
Study NCT02514213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroporation using CELLECTRA®-5P
Description: Electroporation device CELLECTRA®-5P
Study NCT05516615 — intervention group
Intervention type: OTHER
Intervention: 4 minute breathing maneuver
Description: The 4-minute breathing maneuver comprised of 2 minutes of normal breathing and 1-min hyperventilation (rate of 30 breaths or more per minute) followed by a maximal breath-hold.
Study NCT00740194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibition
Description: Letrozole
Study NCT00740194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: Dermestril
Study NCT00854867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Whole Brain Radio Therapy (WBRT) with sequential Depocyte
Study NCT00854867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Whole brain radiotherapy (WBRT) with concomitant Depocyte
Study NCT00914719 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information only
Study NCT00914719 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sexual risk reduction intervention
Study NCT00914719 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sexual risk reduction + alcohol risk reduction component
Study NCT00935961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001 + docetaxel + cisplatin
Description: Patients will receive daily RAD001 (everolimus, per dose escalation scheme) plus concurrent docetaxel (75 mg/m2 intravenously every 3 weeks) + cisplatin (75 mg/m2 intravenously every 3 weeks). Pegfilgrastim (6 mg/subcutaneously) will be administered on day 2 of each cycle. Patients will be followed for toxicity for 30 days after the last dose of RAD001. Patients should undergo re-staging imaging studies within 2 - 6 weeks after the final treatment with cisplatin/docetaxel. After the completion of induction chemotherapy and the 30-day observation period after treatment, patients are removed from the study.
Study NCT01088204 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopy assisted distal gastrectomy
Description: laparoscopy assisted distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
Study NCT01088204 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open distal gastrectomy
Description: open distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
Study NCT06351163 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic reduction
Description: A 1cm longitudinal transumbilical incision was made to insert a 5mm trocar for laparoscope placement. CO2 was injected at 10mmHg and a flow rate of 3L. Two 5-mm working trocars were inserted in the lower right and left abdomen under direct visualization, along with two grasping forceps. The ascending colon was manipulated to locate the intussusception mass. Atraumatic graspers were alternately utilized on the ascending colon to mobilize the intussusceptum, pushing it downward towards the cecum. The first visible part of the terminal ileum was grasped and pulled outward and downward, along with its mesentery, using the right grasper, while the left grasper pulled the intussusceptum's neck in the opposite direction. If resistance was encountered, the terminal ileum could be held with the left hand while the right grasper widened the intussusceptum's neck. After reduction, the intestines were examined for necrosis and possible lead points, followed by routine appendectomy and ileopexy.
Study NCT06351163 — intervention group
Intervention type: PROCEDURE
Intervention: Transumbilical mini-open reduction
Description: If laparoscopic reduction alone was unsuccessful or if bowel resection was required, the intussusceptum was fixed with grasping forceps and brought to the umbilicus for MOR. A 2cm transumbilical incision was created, and a skin retractor was inserted. The underlying fascia was longitudinally extended upward and downward along the linea alba. Upon division of the peritoneum, the actual opening could be expanded up to 5cm, while maintaining the skin incision at 2cm. If the initial incision site proved insufficient for exploration, lateral division of the rectus muscle around the umbilicus on both sides could be performed without cutting the skin, thereby enlarging the surgical field. Manual reduction of the intussusceptum was subsequently carried out, along with bowel resection and anastomosis as indicated.
Study NCT03248167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: 600 mg daily
Study NCT03248167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: This project aims to determine whether cannabidiol (CBD) is effective in treating alcohol use disorder (AUD) comorbid posttraumatic stress disorder (PTSD). To address this aim, investigators will conduct a clinical trial in which CBD will be administered to 48 individuals with AUD comorbid with PTSD, and assess alcohol intake and PTSD symptoms. The aim is to test the hypothesis that CBD will reduce alcohol drinking in individuals with AUD comorbid with PTSD. To test this hypothesis, 48 otherwise healthy adult participants with moderate or severe AUD and PTSD will be randomized to treatment with either CBD (600 mg daily) or placebo, for a period of 6 weeks, such that both participants and study staff are blind to treatment condition.
Study NCT06238336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T cell therapy
Description: The application of CAR-T therapy in the clinic generally involves the in vitro preparation and in vivo infusion of CAR-T, and the specific experimental process is divided into five steps: (1) isolation of T cells from the peripheral blood of the cancer subjects or single harvested single nucleated cells; (2) use of genetic engineering to transfer CAR structural genes that can specifically recognise the tumour cells into the T cells; (3) in vitro cultivation and expansion of CAR-T cells to the desired infusion dose (4) Non-myeloablative chemotherapy is administered prior to the infusion of CAR-T cells, which is used to remove immunosuppressive cells and reduce the tumour load so as to enhance the efficacy of the treatment; (5) CAR-T cells are infused according to the expected dosage, and the efficacy of the treatment is observed and the adverse reactions are closely monitored.
Study NCT02284815 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glutenfree diet
Description: Newly diagnosed children could choose glutenfree diet
Study NCT01786382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI-668
Study NCT01786382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study NCT01786382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Study NCT01786382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Study NCT04186533 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default Option
Description: The default option is a behavioral economics construct that refers to the option a consumer selects if no active choice is made (e.g. opt-out 401K plans, which significantly increase enrollment, compared to active sign up). Participants in the default condition were presented with a prefilled online shopping cart containing groceries that met nutritional requirements based on participants' gender and age.
Study NCT04186533 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education
Description: The nutrition education materials were adapted from materials currently utilized by the Supplemental Nutrition Assistance Education Program
Study NCT01930422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS procedure
Description: The tDCS is a non-invasive neuromodulation method. A stimulator delivers a constant current of low intensity (1-2 mA) applied to the average of two bipolar electrodes placed on the scalp for 20 minutes. This constant current generates a static electric field that selectively modulates the activity of cortical neurones. A tingling sensation under the electrodes appears at the beginning and at the end of stimulation but it is transient and disappears quickly in 30 or 60 seconds.
Study NCT01930422 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: The tDCS placebo differs from the real tDCS by the interruption of stimulation after 30 to 60 seconds and reactivation of this stimulation 30 to 60 seconds before the end of the session, which lasted 20 minutes. The tingling felt at the beginning and the end of the session will be the same as those experienced with real stimulation. The electrodes establishment does not differ with respect to tDCS.
Study NCT00149799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive escitalopram (same dose as received in Phase I) for an additional 6 months.
Study NCT00149799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive placebo for an additional 6 months.
Study NCT03747796 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supine position
Description: The children will be placed in the supine position after ingestion of a standard volume of clear fluid
Study NCT03747796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semi-sitting position
Description: The children will be placed in the semi-sitting position after ingestion of a standard volume of clear fluid
Study NCT01483235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced cardiac rehabilitation group intervention (rCRP).
Description: The rCRP is a comprehensive intervention that will keep the same nature of therapies as the standard cardiac rehabilitation group (sCRP). The difference with the sCRP resides in the number of hospital based exercise sessions; instead of 32 sessions there will be 10 sessions spread throughout the 4 months of intervention (hence, not a shorter program). The rCRP intervention works within the sCRP. Hence, those randomized to the rCRP will be supervised in the same facility and by the same clinical staff as those in the sCRP. Patients from rCRP will receive individual exercise guidelines, an educational package with questions of the week and a diary to record their exercise sessions (logbook), that will serve as a self-monitoring system.
Study NCT01483235 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard cardiac rehabilitation intervention
Description: The standard cardiac rehabilitation is a multidisciplinary four-month intervention to modify ischemic heart disease risk factors and lifestyle behaviours. These programs aim to reduce morbidity and mortality by improving adherence to regular physical activity, a healthy diet and smoking cessation, as well as risk factor modification. Patients receive an initial intake evaluation by a cardiologist, nurse,exercise specialist and dietitian before starting the program. The program consists of 32, twice weekly in-hospital exercise sessions, educational sessions, nutritional counselling, medical care, psychological screening and smoking cessation if needed.
Study NCT02584452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine
Description: 20cc of 2% mepivacaine \<20 minutes prior to in room time.
Study NCT02584452 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adductor canal continuous nerve catheter
Description: Placement of ultrasound guided adductor canal continuous nerve catheter
Study NCT02584452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline as bolus followed by bupivacaine
Description: normal saline as bolus for placement, followed by initiation of 1/8% bupivacaine infusion through adductor canal catheter at 8cc/h
Study NCT02584452 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adductor canal nerve block
Description: ultrasound guided adductor canal nerve block
Study NCT02584452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine and dexamethasone
Description: 10cc of 0.5% ropivacaine + 2 mg dexamethasone (0. 5cc), keeping total injectate at 10.5cc to spare significant proximal spread to femoral nerve
Study NCT02584452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Anesthesia induction will include a propofol bolus.
Study NCT01451957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise - caloric balance
Description: 90 min exercise on Day 1 with meals afterward resulting in caloric balance for the day (i.e.; extra kcals provided to account for energy expended during exercise)\]
Study NCT01451957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Exercise - hyper-caloric diet
Description: Subjects remain sedentary on Day 1 and they ingest meals that are identical to those ingested on the day they performed exercise (i.e.; more calories ingested than expended because no exercise performed).
Study NCT01451957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No exercise - caloric balance
Description: Subjects remain sedentary on Day 1 and they ingest a similar proportion of macronutrients however, the total calories ingested will be lower than the other two trials, resulting in caloric balance for the day.
Study NCT00564265 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Not applied
Study NCT03116841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Vonoprazan 20 mg
Study NCT00122317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eculizumab
Study NCT02252068 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: I-CBT
Description: New cognitive behavioral therapy treatment manual developed to treat co-occurring anxiety and opioid dependency disorders.
Study NCT02252068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-CBT
Description: New cognitive behavioral therapy treatment manual developed to treat co-occurring anxiety and opioid dependency disorders.
Study NCT02252068 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IDC
Description: Individual Drug Counseling manual that has demonstrated efficacy for the treatment of drug dependence.
Study NCT02778425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy+ beta blockers
Description: Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (propranolol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.
Study NCT02778425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy+ PSE+beta blockers
Description: Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (propranolol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
Study NCT00923273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone tablets
Description: 4 mg dose twice daily the day before, the day of, and the day after pemetrexed.
Study NCT02778425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: beta blockers
Description: A standard dose of NSBB (propranolol) was applied to the primary prevention patients according to the Baveno VI recommendations if there were no contraindications.
Study NCT01035983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Frovatriptan 2.5 mg
Study NCT02678650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: volatile anesthetics(isoflurane)
Description: volatile anesthetics wash-in / wash-out operation
Study NCT02678650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: propofol intravenous anesthesia
Description: propofol infusion 3-5μg / kg / h
Study NCT02778425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy
Description: Endoscopic variceal ligation (EVL) is for the primary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
Study NCT02778425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy+ PSE
Description: Endoscopic variceal ligation (EVL) is for the primary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
Study NCT02778425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Somatostatin+Endoscopic therapy
Description: The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
Study NCT02778425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Somatostatin+Endoscopic therapy+PSE
Description: The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
Study NCT02373891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surfolase CR
Description: T1: Surfolase CR (Acebrophylline 200mg) administration after fat intake Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m. 8:00
Study NCT02373891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surfolase CR
Description: T0: Surfolase CR(Acebrophylline 200mg) fasting administration Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m. 8:00
Study NCT04412668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efzofitimod 1 mg/kg
Description: Concentrate for solution for infusion
Study NCT04412668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efzofitimod 3 mg/kg
Description: Concentrate for solution for infusion
Study NCT04412668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Concentrate for solution for infusion
Study NCT04258904 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Skin Care Program
Description: The intervention consists of a Skin Care Program including neat information regarding dermatological complications to the device use, prevention of these and moisturizer to keep healthy skin.